173 related articles for article (PubMed ID: 18516354)
1. The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not at Goal study (SA-NAG).
Ramjeeth A; Butkow N; Raal FJ; Maholwana-Mokgatlhe M
Cardiovasc J Afr; 2008; 19(2):88-94. PubMed ID: 18516354
[TBL] [Abstract][Full Text] [Related]
2. Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).
Boytsov S; Logunova N; Khomitskaya Y;
Cardiovasc Diabetol; 2017 Dec; 16(1):158. PubMed ID: 29246151
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study.
Blom DJ; Ranjith N; Joshi P; Naidoo P; van Tonder A; Musa MG; Joshi S; Leisegang R; Trokis JS; Makan H; Raal FJ
Cardiovasc J Afr; 2020; 31(5):245-251. PubMed ID: 33151240
[TBL] [Abstract][Full Text] [Related]
4. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.
Pearson TA; Laurora I; Chu H; Kafonek S
Arch Intern Med; 2000 Feb; 160(4):459-67. PubMed ID: 10695686
[TBL] [Abstract][Full Text] [Related]
5. Gender and ethnic differences in the control of hyperlipidaemia and other vascular risk factors: insights from the CEntralised Pan-South African survey on tHE Under-treatment of hypercholeSterolaemia (CEPHEUS SA) study.
Rapeport N; Schamroth CL; Blom DJ
Cardiovasc J Afr; 2013 Jul; 24(6):238-42. PubMed ID: 24217264
[TBL] [Abstract][Full Text] [Related]
6. Adherence to prescription guidelines and achievement of treatment goals among persons with coronary heart disease in Tromsø 7.
Pedersen E; Garcia BH; Halvorsen KH; Eggen AE; Schirmer H; Waaseth M
BMC Cardiovasc Disord; 2021 Jan; 21(1):44. PubMed ID: 33478404
[TBL] [Abstract][Full Text] [Related]
7. Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies.
Mitchell S; Roso S; Samuel M; Pladevall-Vila M
BMC Cardiovasc Disord; 2016 Apr; 16():74. PubMed ID: 27114245
[TBL] [Abstract][Full Text] [Related]
8. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
[TBL] [Abstract][Full Text] [Related]
9. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
10. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
[TBL] [Abstract][Full Text] [Related]
11. Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey.
Park JE; Chiang CE; Munawar M; Pham GK; Sukonthasarn A; Aquino AR; Khoo KL; Chan HW
Eur J Prev Cardiol; 2012 Aug; 19(4):781-94. PubMed ID: 21450606
[TBL] [Abstract][Full Text] [Related]
12. Current cardiovascular risk management patterns with special focus on lipid lowering in daily practice in Switzerland.
Jaussi A; Noll G; Meier B; Darioli R
Eur J Cardiovasc Prev Rehabil; 2010 Jun; 17(3):363-72. PubMed ID: 20168234
[TBL] [Abstract][Full Text] [Related]
13. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group.
Schrott HG; Bittner V; Vittinghoff E; Herrington DM; Hulley S
JAMA; 1997 Apr 23-30; 277(16):1281-6. PubMed ID: 9109465
[TBL] [Abstract][Full Text] [Related]
14. Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline.
Journath G; Hambraeus K; Hagström E; Pettersson B; Löthgren M
BMC Cardiovasc Disord; 2017 Aug; 17(1):224. PubMed ID: 28814290
[TBL] [Abstract][Full Text] [Related]
15. Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study.
Hammoudeh AJ; Echtay A; Ghanem GY; Haddad J;
Curr Med Res Opin; 2014 Oct; 30(10):1957-65. PubMed ID: 24889279
[TBL] [Abstract][Full Text] [Related]
16. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS).
Raal FJ; Blom DJ; Naidoo S; Bramlage P; Brudi P
Cardiovasc J Afr; 2013 Sep; 24(8):330-8. PubMed ID: 24240385
[TBL] [Abstract][Full Text] [Related]
18. Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008.
Kuznik A; Mardekian J
Cardiovasc Diabetol; 2011 Apr; 10():31. PubMed ID: 21496321
[TBL] [Abstract][Full Text] [Related]
19. How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL.
Averna M; Stroes E;
Atheroscler Suppl; 2017 Apr; 26():16-24. PubMed ID: 28434480
[TBL] [Abstract][Full Text] [Related]
20. Extent of control of cardiovascular risk factors and adherence to recommended therapies in US multiethnic adults with coronary heart disease: from a 2005-2006 national survey.
Vulic D; Lee BT; Dede J; Lopez VA; Wong ND
Am J Cardiovasc Drugs; 2010; 10(2):109-14. PubMed ID: 20334448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
